Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.47 |
| ▸ | PGR | P06401 | 7/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278672 | 0.85 | NR3C1 (0.52) | NR3C1PGRNR3C2AR | |
| SCHEMBL4002508 | 0.80 | NR3C1 (0.65) | NR3C1PGRNR3C2AR | |
| SCHEMBL4890732 | 0.79 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL5645065 | 0.78 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL4738933 | 0.77 | NR3C1 (0.74) | NR3C1PGRNR3C2AR | |
| SCHEMBL5645477 | 0.77 | NR3C1 (0.51) | NR3C1PGRNR3C2AR | |
| SCHEMBL4620586 | 0.77 | NR3C1 (0.51) | NR3C1PGRNR3C2AR | |
| SCHEMBL4740189 | 0.76 | NR3C1 (0.57) | NR3C1PGRNR3C2 | |
| SCHEMBL4621610 | 0.76 | NR3C1 (0.73) | NR3C1PGRNR3C2AR | |
| SCHEMBL5641716 | 0.76 | NR3C1 (0.59) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008077647-A2 | ALPHA- AMINO ALCOHOLS AS NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077647-A2 | ALPHA- AMINO ALCOHOLS AS NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188448-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC1, PGRMC2 | NR3C1 65/4885PGR 1/4885NR3C2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.